Shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Analysts have set a 1 year consensus target price of $72.00 for the company and are anticipating that the company will post $0.36 earnings per share for the current quarter, according to Zacks. Zacks has also assigned BioSpecifics Technologies Corp an industry rank of 106 out of 265 based on the ratings given to related companies.

Several research firms have recently weighed in on BSTC. Zacks Investment Research cut shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Monday, May 15th. BidaskClub cut shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, HC Wainwright set a $72.00 price target on shares of BioSpecifics Technologies Corp and gave the stock a “buy” rating in a report on Thursday, August 10th.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/25/zacks-biospecifics-technologies-corp-bstc-receives-average-rating-of-strong-buy-from-brokerages.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its position in BioSpecifics Technologies Corp by 122.6% in the first quarter. Bank of America Corp DE now owns 2,489 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,371 shares in the last quarter. US Bancorp DE boosted its position in BioSpecifics Technologies Corp by 1.1% in the second quarter. US Bancorp DE now owns 3,455 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 36 shares in the last quarter. American International Group Inc. boosted its position in BioSpecifics Technologies Corp by 7.1% in the first quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 222 shares in the last quarter. Public Employees Retirement System of Ohio boosted its position in BioSpecifics Technologies Corp by 16.2% in the first quarter. Public Employees Retirement System of Ohio now owns 3,674 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 513 shares in the last quarter. Finally, CAPROCK Group Inc. purchased a new position in BioSpecifics Technologies Corp during the second quarter worth approximately $206,000. 54.81% of the stock is currently owned by institutional investors and hedge funds.

BioSpecifics Technologies Corp (NASDAQ:BSTC) opened at 45.88 on Friday. BioSpecifics Technologies Corp has a 1-year low of $36.00 and a 1-year high of $58.79. The firm has a market cap of $328.68 million, a price-to-earnings ratio of 28.15 and a beta of 1.76. The firm has a 50-day moving average price of $48.52 and a 200-day moving average price of $51.43.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Get a free copy of the Zacks research report on BioSpecifics Technologies Corp (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.